REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

NCT00715364 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Stroke

Interventions

DRUG: NTx™-265: rhCG, then rEPO
DRUG: Saline Placebo

Sponsor

Stem Cell Therapeutics Corp.